Related Experiment Video
Updated: Jan 27, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational
Ruth Nussinov1,2, Hyunbum Jang1, Chung-Jung Tsai1
1Computational Structural Biology Section, Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.
Abstract:
At the root of the so-called precision medicine or precision oncology, which is our focus here, is the hypothesis that cancer treatment would be considerably better if therapies were guided by a tumor's genomic alterations. This hypothesis has sparked major initiatives focusing on whole-genome and/or exome sequencing, creation of large databases, and developing tools for their statistical analyses-all aspiring to identify actionable alterations, and thus molecular targets, in a patient. At the center of the massive amount of collected sequence data is their interpretations that largely rest on statistical analysis and phenotypic observations. Statistics is vital, because it guides identification of cancer-driving alterations. However, statistics of mutations do not identify a change in protein conformation; therefore, it may not define sufficiently accurate actionable mutations, neglecting those that are rare. Among the many thematic overviews of precision oncology, this review innovates by further comprehensively including precision pharmacology, and within this framework, articulating its protein structural landscape and consequences to cellular signaling pathways. It provides the underlying physicochemical basis, thereby also opening the door to a broader community.
Insights
Precision oncology uses genomic data to tailor cancer treatments. This review integrates precision pharmacology, examining protein structures and signaling pathways for improved therapeutic strategies.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Precision medicine and oncology aim to improve cancer treatment by aligning therapies with a patient's tumor genomic alterations.
- Major initiatives involve whole-genome sequencing, large databases, and statistical analysis to identify actionable alterations and molecular targets.
Purpose of the Study:
- To provide a comprehensive review of precision oncology, uniquely incorporating precision pharmacology.
- To articulate the protein structural landscape and its impact on cellular signaling pathways within the precision pharmacology framework.
Main Methods:
- Review of existing literature on precision oncology, genomic sequencing, and statistical analysis of cancer data.
- Integration of principles from structural biology and pharmacology to analyze protein alterations and their functional consequences.
- Exploration of the physicochemical basis of molecular interactions in cancer signaling.
Main Results:
- Statistical analysis of genomic data is crucial but may not fully capture the functional impact of mutations, especially rare ones, by not identifying protein conformational changes.
- Precision pharmacology offers a deeper understanding by considering the structural and functional consequences of genomic alterations on cellular pathways.
- The review highlights the importance of understanding protein structure and signaling for identifying effective, actionable mutations.
Conclusions:
- Integrating precision pharmacology with precision oncology provides a more complete picture of cancer biology and treatment strategies.
- Understanding the protein structural landscape and its effects on cellular signaling is essential for advancing precision cancer therapy.
- This approach offers a physicochemical basis for interpreting genomic data, potentially improving the identification of rare but actionable mutations.
Related Concept Videos
Conformity
Mutations
Hardy-Weinberg Principle
The Uncertainty Principle
Empirical Method to Interpret Standard Deviation
This rule is used widely in statistics to calculate the proportion of data values...
Cancers Originate from Somatic Mutations in a Single Cell

